Breckenridge Pharmaceutical, Inc.
Breckenridge Pharmaceutical, Inc. lists 75 drug products in the FDA National Drug Code directory.
Products
| NDC | Product | Strength | Type |
|---|---|---|---|
| 51991-620 | Anastrozole Tablet | Anastrozole 1 mg/1 | Rx |
| 51991-074 | Ascomp with Codeine Capsule | Butalbital 50 mg/1; Aspirin 325 mg/1; Caffeine 40 mg/1; Codeine Phosphate 30 mg/1 | Rx |
| 51991-928 | Asenapine Tablet | Asenapine Maleate 2.5 mg/1 | Rx |
| 51991-361 | Asenapine Tablet | Asenapine Maleate 10 mg/1 | Rx |
| 51991-360 | Asenapine Tablet | Asenapine Maleate 10 mg/1 | Rx |
| 51991-359 | Asenapine Tablet | Asenapine Maleate 5 mg/1 | Rx |
| 51991-358 | Asenapine Tablet | Asenapine Maleate 5 mg/1 | Rx |
| 51991-073 | Butalbital, Acetaminophen, Caffeine and Codeine Phosphate Capsule | Butalbital 50 mg/1; Acetaminophen 325 mg/1; Caffeine 40 mg/1; Codeine Phosphate 30 mg/1 | Rx |
| 51991-999 | Dehydrated Alcohol Injection, Solution | Alcohol 1 mL/mL | Rx |
| 51991-006 | Desvenlafaxine Tablet, Extended Release | Desvenlafaxine Succinate 25 mg/1 | Rx |
| 51991-311 | Desvenlafaxine Tablet, Extended Release | Desvenlafaxine Succinate 50 mg/1 | Rx |
| 51991-312 | Desvenlafaxine Tablet, Extended Release | Desvenlafaxine Succinate 100 mg/1 | Rx |
| 51991-746 | Duloxetine Delayed-Release Capsule, Delayed Release Pellets | Duloxetine Hydrochloride 20 mg/1 | Rx |
| 51991-747 | Duloxetine Delayed-Release Capsule, Delayed Release Pellets | Duloxetine Hydrochloride 30 mg/1 | Rx |
| 51991-748 | Duloxetine Delayed-Release Capsule, Delayed Release Pellets | Duloxetine Hydrochloride 60 mg/1 | Rx |
| 51991-750 | Duloxetine Delayed-Release Capsule, Delayed Release Pellets | Duloxetine Hydrochloride 40 mg/1 | Rx |
| 51991-878 | Eplerenone Tablet, Film Coated | Eplerenone 50 mg/1 | Rx |
| 51991-877 | Eplerenone Tablet, Film Coated | Eplerenone 25 mg/1 | Rx |
| 51991-623 | Estradiol / Norethindrone Acetate Tablet, Film Coated | Estradiol .5 mg/1; Norethindrone Acetate .1 mg/1 | Rx |
| 51991-474 | Estradiol / Norethindrone Acetate Tablet, Film Coated | Estradiol 1 mg/1; Norethindrone Acetate .5 mg/1 | Rx |
| 51991-992 | Everolimus Tablet, For Suspension | Everolimus 5 mg/1 | Rx |
| 51991-381 | Everolimus Tablet | Everolimus .75 mg/1 | Rx |
| 51991-380 | Everolimus Tablet | Everolimus .5 mg/1 | Rx |
| 51991-379 | Everolimus Tablet | Everolimus .25 mg/1 | Rx |
| 51991-821 | Everolimus Tablet | Everolimus 2.5 mg/1 | Rx |
| 51991-822 | Everolimus Tablet | Everolimus 5 mg/1 | Rx |
| 51991-823 | Everolimus Tablet | Everolimus 7.5 mg/1 | Rx |
| 51991-824 | Everolimus Tablet | Everolimus 10 mg/1 | Rx |
| 51991-985 | Everolimus Tablet | Everolimus 1 mg/1 | Rx |
| 51991-990 | Everolimus Tablet, For Suspension | Everolimus 2 mg/1 | Rx |
| 51991-991 | Everolimus Tablet, For Suspension | Everolimus 3 mg/1 | Rx |
| 51991-005 | Exemestane Tablet, Film Coated | Exemestane 25 mg/1 | Rx |
| 51991-735 | Granisetron Hydrochloride Tablet | Granisetron Hydrochloride 1 mg/1 | Rx |
| 51991-348 | Lacosamide Tablet, Film Coated | Lacosamide 50 mg/1 | Rx |
| 51991-349 | Lacosamide Tablet, Film Coated | Lacosamide 100 mg/1 | Rx |
| 51991-350 | Lacosamide Tablet, Film Coated | Lacosamide 150 mg/1 | Rx |
| 51991-351 | Lacosamide Tablet, Film Coated | Lacosamide 200 mg/1 | Rx |
| 51991-759 | Letrozole Tablet | Letrozole 2.5 mg/1 | Rx |
| 51991-002 | Methadone Hydrochloride Injection, Solution | Methadone Hydrochloride 10 mg/mL | Rx |
| 51991-191 | Methscopolamine Bromide Tablet | Methscopolamine Bromide 2.5 mg/1 | Rx |
| 51991-192 | Methscopolamine Bromide Tablet | Methscopolamine Bromide 5 mg/1 | Rx |
| 51991-144 | Methylergonovine Maleate Injection | Methylergonovine Maleate .2 mg/mL | Rx |
| 51991-034 | Milnacipran Hydrochloride Tablet | Milnacipran Hydrochloride 12.5 mg/1 | Rx |
| 51991-036 | Milnacipran Hydrochloride Tablet | Milnacipran Hydrochloride 50 mg/1 | Rx |
| 51991-037 | Milnacipran Hydrochloride Tablet | Milnacipran Hydrochloride 100 mg/1 | Rx |
| 51991-876 | Milnacipran Hydrochloride Tablet | Milnacipran Hydrochloride 25 mg/1 | Rx |
| 51991-983 | Norepinephrine Bitartrate Injection, Solution, Concentrate | Norepinephrine Bitartrate 1 mg/mL | Rx |
| 51991-055 | Oxcarbazepine Tablet, Film Coated | Oxcarbazepine 600 mg/1 | Rx |
| 51991-054 | Oxcarbazepine Tablet, Film Coated | Oxcarbazepine 300 mg/1 | Rx |
| 51991-292 | Oxcarbazepine Tablet, Film Coated | Oxcarbazepine 150 mg/1 | Rx |
| 51991-293 | Oxcarbazepine Tablet, Film Coated | Oxcarbazepine 300 mg/1 | Rx |
| 51991-294 | Oxcarbazepine Tablet, Film Coated | Oxcarbazepine 600 mg/1 | Rx |
| 51991-053 | Oxcarbazepine Tablet, Film Coated | Oxcarbazepine 150 mg/1 | Rx |
| 51991-974 | Penicillamine Capsule | Penicillamine 250 mg/1 | Rx |
| 51991-342 | Pomalidomide Capsule | Pomalidomide 1 mg/1 | Rx |
| 51991-343 | Pomalidomide Capsule | Pomalidomide 2 mg/1 | Rx |
| 51991-344 | Pomalidomide Capsule | Pomalidomide 3 mg/1 | Rx |
| 51991-346 | Pomalidomide Capsule | Pomalidomide 4 mg/1 | Rx |
| 51991-820 | propranolol hydrochloride Capsule, Extended Release | Propranolol Hydrochloride 160 mg/1 | Rx |
| 51991-817 | propranolol hydrochloride Capsule, Extended Release | Propranolol Hydrochloride 60 mg/1 | Rx |
| 51991-818 | propranolol hydrochloride Capsule, Extended Release | Propranolol Hydrochloride 80 mg/1 | Rx |
| 51991-819 | propranolol hydrochloride Capsule, Extended Release | Propranolol Hydrochloride 120 mg/1 | Rx |
| 51991-897 | Rivastigmine Transdermal System Patch, Extended Release | Rivastigmine 4.6 mg/24h | Rx |
| 51991-898 | Rivastigmine Transdermal System Patch, Extended Release | Rivastigmine 9.5 mg/24h | Rx |
| 51991-899 | Rivastigmine Transdermal System Patch, Extended Release | Rivastigmine 13.3 mg/24h | Rx |
| 51991-526 | Terbinafine Hydrochloride Tablet | Terbinafine Hydrochloride 250 mg/1 | Rx |
| 51991-907 | Tetracycline Hydrochloride Capsule | Tetracycline Hydrochloride 500 mg/1 | Rx |
| 51991-906 | Tetracycline Hydrochloride Capsule | Tetracycline Hydrochloride 250 mg/1 | Rx |
| 51991-963 | Tofacitinib Tablet | Tofacitinib Citrate 10 mg/1 | Rx |
| 51991-329 | Tofacitinib Tablet | Tofacitinib Citrate 5 mg/1 | Rx |
| 51991-946 | Trimipramine Capsule | Trimipramine Maleate 100 mg/1 | Rx |
| 51991-945 | Trimipramine Capsule | Trimipramine Maleate 50 mg/1 | Rx |
| 51991-944 | Trimipramine Capsule | Trimipramine Maleate 25 mg/1 | Rx |
| 51991-981 | Zolpidem Tartrate Tablet, Extended Release | Zolpidem Tartrate 6.25 mg/1 | Rx |
| 51991-982 | Zolpidem Tartrate Tablet, Extended Release | Zolpidem Tartrate 12.5 mg/1 | Rx |
Recalls by Breckenridge Pharmaceutical, Inc.
- D-0583-2026 Jun 17, 2026 · Class II
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit - D-0582-2026 Jun 17, 2026 · Class II
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit - D-0522-2026 May 13, 2026 · Class II
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit - D-0216-2026 Dec 10, 2025 · Class II
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit - D-0215-2026 Dec 10, 2025 · Class II
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit - D-0100-2026 Nov 5, 2025 · Class II
CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm. - D-0621-2025 Sep 17, 2025 · Class II
CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit. - D-0580-2025 Aug 20, 2025 · Class II
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. - D-0552-2025 Aug 13, 2025 · Class II
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit - D-0511-2025 Jul 16, 2025 · Class II
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit - D-0308-2025 Apr 9, 2025 · Class II
CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit. - D-0271-2025 Mar 19, 2025 · Class II
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. - D-0270-2025 Mar 19, 2025 · Class II
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. - D-0269-2025 Mar 19, 2025 · Class II
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. - D-0279-2019 Nov 21, 2018 · Class III
Failed Stability Specifications: Out-of-Specification results obtained for particle size distribution during stability testing.